Company news
Shield Therapeutics Plc (LSE:STX) news
Shield Therapeutics Plc news releases on 6ix. Latest, Sep 30, 2026: Total Voting Rights
Press releases & updates
Total Voting Rights
September 30, 2026
Shield assumes full control of ACCRUFeR® in the US
August 27, 2026
Interim results for the six months ended 30 Jun 26
August 20, 2026
Q2 and H1 2026 Trading Update
July 30, 2026
ACCRUFeR® Phase 3 pediatric trial published
July 28, 2026
Results of 2026 Annual General Meeting
June 18, 2026
Q1 2026 Trading Update
May 1, 2026
Enrollment in Phase II Clinical Trial for ACCRUFeR
April 27, 2026
Audited results for year ended 31 December 2025
April 9, 2026
Publication of Report, Reinforcing FDA Approval
April 1, 2026
Total Voting Rights
March 31, 2026
Chinese NMPA Accepts MAA Submission for ACCRUFeR®
March 3, 2026
FDA Grants additional Exclusivity for ACCRUFeR
February 9, 2026
Approval for ACCRUFeR in China expected in Q1 2026
January 30, 2026
Q4 2025 Trading Update
January 21, 2026
Block listing 6 Monthly Return
January 2, 2026
FDA approves extension for ACCRUFeR®
December 22, 2025
Block Listing Application
December 18, 2025
Shield Wins Gold at Titan Branding Awards
December 11, 2025
Amends Senior Secured Debt Financing
December 3, 2025
Initiation of a Phase II Clinical Trial in Japan
November 14, 2025
ACCRUFeR Pediatric PK Results to be Presented
November 11, 2025
ACCRUFeR receives Authorisation by Korean Ministry
November 7, 2025
Shield Therapeutics : Q3 2025 Trading Update
October 24, 2025
Q3 2025 Trading Update
October 23, 2025
Grant of Share Options to Chief Executive Officer
October 14, 2025
Positive efficacy and tolerance in pediatric trial
October 1, 2025
£1.5 million placing supporting growth of ACCRUFeR
September 15, 2025
ACCRUFeR® assigned Priority Review in US by FDA
September 4, 2025
Interim results for the six months ended 30 Jun 25
September 3, 2025
Data published -European Journal of Heart Failure
August 27, 2025
Shield Therapeutics : Interim results for the six months ended 30 June 2025
August 21, 2025
Q2 2025 Trading Update
July 23, 2025
Result of AGM
May 22, 2025
Shield Therapeutics : Annual Report and Accounts for the year ended 2024
April 25, 2025
Audited results for the year ended 31 Dec 2024
April 24, 2025
Licence Agreement in Japan for ACCRUFeR®
April 22, 2025
Q1 2025 Trading Update
April 17, 2025
ACCRUFeR® launched in Canada
March 11, 2025
PDMR Transaction Notification
February 13, 2025
Unaudited full year trading update
February 5, 2025
Anders Lundstrom appointed CEO
January 27, 2025
Result of General Meeting & Total Voting Rights
December 24, 2024
Results of RetailBook Offer
December 23, 2024
RetailBook Offer
December 6, 2024
Hardman & Co Investor Forum Research on Shiel...
November 21, 2024
Hardman & Co Video Event: Shield Therapeutics...
November 11, 2024
Q3 Trading Update
October 29, 2024
Results from Phase 3 paediatric study
September 25, 2024
Hardman & Co Research on Shield Therapeutics ...
September 11, 2024